DDInter298 DDInter1682
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium aurothiomalate
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium aurothiomalate
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is upregulated by {v} (Compound) Teniposide
Teniposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium aurothiomalate
Carboplatin {u} (Compound) binds {v} (Gene) MT2A
MT2A {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium aurothiomalate
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A1
SLC31A1 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium aurothiomalate
Carboplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium aurothiomalate
Carboplatin {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium aurothiomalate
Carboplatin {u} (Compound) causes {v} (Side Effect) Phlebitis
Phlebitis {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Sodium aurothiomalate
Carboplatin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Sodium aurothiomalate
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Carboplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Carboplatin (Compound) binds SLC31A2 (Gene) and SLC31A2 (Gene) is upregulated by Teniposide (Compound) and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Carboplatin (Compound) binds MT2A (Gene) and MT2A (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Carboplatin (Compound) binds SLC31A1 (Gene) and SLC31A1 (Gene) is bound by Bortezomib (Compound) and SLC31A1 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Carboplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Oxaliplatin (Compound) and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Carboplatin (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Carboplatin (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Sodium aurothiomalate
Carboplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Sodium aurothiomalate